Business Description
Sansure Biotech Inc
ISIN : CNE1000043J1
Share Class Description:
SHSE:688289: Class ACompare
Compare
Traded in other countries / regions
688289.China IPO Date
2020-08-28Description
Sansure Biotech Inc is engaged in production and sales of diagnostic reagents and instruments. The company produces Class I medical devices, Class II medical devices, Class III medical devices, general instruments and meters, medical raw materials, medical laboratory equipment and appliances, and medical accessories.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 10.49 | |||||
| Equity-to-Asset | 0.84 | |||||
| Debt-to-Equity | 0.06 | |||||
| Debt-to-EBITDA | 1.57 | |||||
| Interest Coverage | 11 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 8.07 | |||||
| Beneish M-Score | -2.75 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -41.6 | |||||
| 3-Year EBITDA Growth Rate | -45.6 | |||||
| 3-Year EPS without NRI Growth Rate | -70.5 | |||||
| 3-Year Book Growth Rate | 15.1 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 97.36 | |||||
| Future 3-5Y Total Revenue Growth Rate | 36.52 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 37.19 | |||||
| 9-Day RSI | 40.68 | |||||
| 14-Day RSI | 44.3 | |||||
| 6-1 Month Momentum % | 24.22 | |||||
| 12-1 Month Momentum % | 18.73 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 8.04 | |||||
| Quick Ratio | 7.45 | |||||
| Cash Ratio | 6.4 | |||||
| Days Inventory | 434.03 | |||||
| Days Sales Outstanding | 176.66 | |||||
| Days Payable | 478.9 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 2.05 | |||||
| Dividend Payout Ratio | 1.68 | |||||
| 3-Year Dividend Growth Rate | 11.3 | |||||
| Forward Dividend Yield % | 3.24 | |||||
| 5-Year Yield-on-Cost % | 1.98 | |||||
| 3-Year Average Share Buyback Ratio | 0.2 | |||||
| Shareholder Yield % | -0.31 |
Profitability Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 77.18 | |||||
| Operating Margin % | 14.31 | |||||
| Net Margin % | 18.44 | |||||
| FCF Margin % | -10.66 | |||||
| ROE % | 3.55 | |||||
| ROA % | 3.04 | |||||
| ROIC % | 5.41 | |||||
| ROC (Joel Greenblatt) % | 19.44 | |||||
| ROCE % | 3.56 | |||||
| Years of Profitability over Past 10-Year | 6 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 51.16 | |||||
| Forward PE Ratio | 29.25 | |||||
| PE Ratio without NRI | 52.96 | |||||
| PS Ratio | 9.39 | |||||
| PB Ratio | 1.81 | |||||
| Price-to-Tangible-Book | 1.93 | |||||
| Price-to-Operating-Cash-Flow | 66.18 | |||||
| EV-to-EBIT | 31.66 | |||||
| EV-to-EBITDA | 31.66 | |||||
| EV-to-Revenue | 6.23 | |||||
| EV-to-FCF | -58.61 | |||||
| Price-to-Peter-Lynch-Fair-Value | 7.63 | |||||
| Price-to-Graham-Number | 2.13 | |||||
| Price-to-Net-Current-Asset-Value | 2.97 | |||||
| Price-to-Net-Cash | 4.05 | |||||
| Earnings Yield (Greenblatt) % | 3.16 | |||||
| FCF Yield % | -1.14 | |||||
| Forward Rate of Return (Yacktman) % | 15.38 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Sansure Biotech Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 1,407.157 | ||
| EPS (TTM) (Â¥) | 0.44 | ||
| Beta | 1.02 | ||
| Volatility % | 37.23 | ||
| 14-Day RSI | 44.3 | ||
| 14-Day ATR (Â¥) | 0.926742 | ||
| 20-Day SMA (Â¥) | 22.991 | ||
| 12-1 Month Momentum % | 18.73 | ||
| 52-Week Range (Â¥) | 16.08 - 25.58 | ||
| Shares Outstanding (Mil) | 582.39 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Sansure Biotech Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Sansure Biotech Inc Stock Events
| Event | Date | Price(Â¥) | ||
|---|---|---|---|---|
| No Event Data | ||||
Sansure Biotech Inc Frequently Asked Questions
What is Sansure Biotech Inc(SHSE:688289)'s stock price today?
The current price of SHSE:688289 is ¥22.51. The 52 week high of SHSE:688289 is ¥25.58 and 52 week low is ¥16.08.
When is next earnings date of Sansure Biotech Inc(SHSE:688289)?
The next earnings date of Sansure Biotech Inc(SHSE:688289) is .
Does Sansure Biotech Inc(SHSE:688289) pay dividends? If so, how much?
The Dividend Yield %  of Sansure Biotech Inc(SHSE:688289) is 2.05% (As of Today), Highest Dividend Payout Ratio of Sansure Biotech Inc(SHSE:688289) was 5.83. The lowest was 0.11. And the median was 0.3. The  Forward Dividend Yield % of Sansure Biotech Inc(SHSE:688289) is 3.24%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers